A Multiplex RT-QPCR Assay of ONECUT2, EZH2, and BRCA2 for the Detection of Clinically Significant Prostate Cancer in Needle Biopsies
Cancers · 14.09.2026 · 18 (18) · 2962
DOI: 10.3390/cancers18182962 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 14.09.2026. Verfasst von Yuta Inoue und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90089, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, V Foundation for Cancer Research, Vicky Joseph Cancer Research Foundation.
Abstract (Originalsprache)
Background/Objectives: Needle biopsy-based molecular assays that are sensitive, cost-effective, and reproducible could improve prostate cancer (PCa) diagnosis and risk stratification. We developed a compact, biologically informed gene expression signature panel (ONECUT2, EZH2, BRCA2) for cancer detection and aggressiveness stratification.
Methods
We designed and validated a multiplex real-time RT-qPCR assay for ONECUT2, EZH2, and BRCA2. Biomarker selection was guided by The Cancer Genome Atlas Prostate Adenocarcinoma (TCGA-PRAD) and Gene Expression Omnibus (GEO) cohort analyses. The assay was applied to 979 ex vivo needle biopsy cores from 255 radical prostatectomy specimens; machine-learning models (Random Forest, AdaBoost, Elastic Net) generated an RNA signature. Diagnostic and prognostic performance was assessed by the area under the receiver operating characteristic curve (AUC), model comparisons by DeLong’s test, and biochemical recurrence-free survival (BCR) by Kaplan–Meier and Cox proportional hazards analyses. Reproducibility based on sample pairs was assessed by intraclass correlation coefficients (ICC).
Results
The three-gene expression signature (ONECUT2, EZH2, and BRCA2) robustly discriminated malignant from non-malignant tissue (AUC = 0.91) and identified clinically significant cancer (Gleason Grade Group [GG] ≥ 2 vs. GG 0–1, AUC = 0.89) within biopsy cores. However, it had limited performance for advanced patient-level features (e.g., pathological GG3–5, AUC = 0.63). In contrast, ONECUT2 gene-body methylation significantly stratified pathological aggressiveness (pathological GG3–5, AUC = 0.79; aggressive disease, AUC = 0.75) and demonstrated superior assay stability (methylation ICC 0.58–0.70 vs. RNA ICC 0.38–0.61). Furthermore, ONECUT2 DNA methylation significantly stratified BCR-free survival (hazard ratio = 3.90, p = 0.023), whereas the RNA signature showed a modest trend (hazard ratio = 1.88, p = 0.053). Notably, integrating DNA methylation with the three-gene expression signature (combined model) significantly improved predictive accuracy for adverse features (e.g., extraprostatic extension, ΔAUC = 0.20, p = 0.02) compared to the three-gene expression signature alone.
Conclusions
While a multiplex RT-qPCR panel (ONECUT2, EZH2, and BRCA2) excels at core-level cancer detection, it lacks the resolution for aggressiveness classification. In contrast, ONECUT2 DNA methylation provides superior analytical reproducibility, robust stratification of cancer aggressiveness, and long-term recurrence risk estimation. These findings suggest that integrating transcriptional and epigenetic markers into a multimodal framework could provide complementary information to refine risk stratification in PCa.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90089, USA.
- Department of Urology, Kyoto Prefectural University of Medicine, Kamigyo-Ku, Kyoto 602-8566, Japan.
- Department of Radiology/Neurology, University of Southern California, Los Angeles, CA 90089, USA.
- Department of Urology, Chongqing University Cancer Hospital, Chongqing 400044, China.
- Department of Pathology, USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90089, USA.
- Department of Urology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima 739-0046, Japan.
ORCID-Profile: Yuta Inoue, Federico Eskenazi, Manju Aron, Yohei Sekino, Andre Luis Abreu, Gangning Liang
Förderung
- NCI NIH HHS
- V Foundation for Cancer Research
- Vicky Joseph Cancer Research Foundation
- National Cancer Institute
Zitieren
APA
Inoue, Y., Cen, S. Y., Kaneko, M., Yuan, G., Deng, Z., Lu, R., Gong, M. C., Zhang, J., Eskenazi, F., Konganige, S., Aron, M., Sekino, Y., Iwata, T., Fujihara, A., Ukimura, O., Gill, I., Abreu, A. L., & Liang, G. (2026). A Multiplex RT-QPCR Assay of ONECUT2, EZH2, and BRCA2 for the Detection of Clinically Significant Prostate Cancer in Needle Biopsies. Cancers, 18(18), 2962. https://doi.org/10.3390/cancers18182962
Vancouver
Inoue Y, Cen SY, Kaneko M, Yuan G, Deng Z, Lu R, et al. A Multiplex RT-QPCR Assay of ONECUT2, EZH2, and BRCA2 for the Detection of Clinically Significant Prostate Cancer in Needle Biopsies. Cancers. 2026;18(18):2962. doi:10.3390/cancers18182962
BibTeX
@article{Inoue2026,
author = {Inoue, Yuta and Cen, Steven Yong and Kaneko, Masatomo and Yuan, Gangjun and Deng, Zhenzhong and Lu, Rongying and Gong, Michelle C and Zhang, Jerry and Eskenazi, Federico and Konganige, Shiran and Aron, Manju and Sekino, Yohei and Iwata, Tsuyoshi and Fujihara, Atsuko and Ukimura, Osamu and Gill, Inderbir and Abreu, Andre Luis and Liang, Gangning},
title = {A Multiplex RT-QPCR Assay of ONECUT2, EZH2, and BRCA2 for the Detection of Clinically Significant Prostate Cancer in Needle Biopsies},
journal = {Cancers},
year = {2026},
volume = {18},
number = {18},
pages = {2962},
doi = {10.3390/cancers18182962}
}
EUVIMED